Get the Stockscreener App
0.8901
3.51%
-0.0324
After Hours:
.89
-0.000100
-0.01%
Tela Bio Inc stock is traded at $0.8901, with a volume of 95,664.
It is down -3.51% in the last 24 hours and up +42.53% over the past month.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
See More
Previous Close:
$0.9225
Open:
$0.91
24h Volume:
95,664
Relative Volume:
0.54
Market Cap:
$39.85M
Revenue:
$80.28M
Net Income/Loss:
$-38.83M
P/E Ratio:
-1.0701
EPS:
-0.8318
Net Cash Flow:
$-28.67M
1W Performance:
-1.65%
1M Performance:
+42.53%
6M Performance:
-23.92%
1Y Performance:
-38.61%
1-Day Range:
$0.8601
$0.92
1-Week Range:
$0.7861
$1.045
52-Week Range:
$0.5011
$2.20
Tela Bio Inc Stock (TELA) Company Profile
Name
Tela Bio Inc
Sector
Industry
Phone
484-320-2930
Address
1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA
Compare TELA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELA
Tela Bio Inc
|
0.8901 | 41.30M | 80.28M | -38.83M | -28.67M | -0.8318 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tela Bio Inc Stock (TELA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-31-22 | Initiated | Lake Street | Buy |
| Dec-03-19 | Initiated | Canaccord Genuity | Buy |
| Dec-03-19 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-19 | Initiated | Jefferies | Buy |
| Dec-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Tela Bio Inc Stock (TELA) Latest News
TELA Bio Expands Europe Sales as U.S. Growth Slows - MyChesCo
TELA Stock Price, Quote & Chart | TELA BIO INC (NASDAQ:TELA) - ChartMill
TELA Bio Inc. (TELA) Edges Lower, Tests Key Support After 2.7% DeclineUser Trade Ideas - Newser
Tela Bio Eyes Second-Half Ramp After Mixed Quarter - TipRanks
TELA Bio (TELA) Q1 2026 Results Miss Estimates — EPS $-0.21 vs $-0.19Retail Earnings Report - Newser
TELA Bio Healthcare Story Faces New Market Scrutiny - Kalkine Media
TELA Bio (NASDAQ: TELA) holder reports 2.44M shares, 5.5% stake - Stock Titan
Analysts Have Been Trimming Their TELA Bio, Inc. (NASDAQ:TELA) Price Target After Its Latest Report - simplywall.st
Earnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25 - Yahoo Finance
About Us | Oil & Gas JournalTELA Bio, Inc.Common stock (Nasdaq:TELA) Stock Quote - FinancialContent
Becton Dickinson stock (US0718131099): Antitrust case survives dismissal - AD HOC NEWS
TELA Bio, Inc. (TELA) reports Q1 loss, beats revenue estimates - MSN
Lake Street Keeps Their Buy Rating on TELA Bio (TELA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), UnitedHealth (UNH) and TELA Bio (TELA) - The Globe and Mail
Tela Bio Earnings Call Balances Momentum and Risk - TipRanks
TELA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Becton Hernia Mesh Antitrust Case Survives Dismissal - Law360
TELA Bio (NASDAQ: TELA) Q1 2026 revenue edges up as net loss widens - Stock Titan
TELA outlines at least 8% 2026 revenue growth while guiding Q2 revenue to about $20.0M - MSN
Q1 2026 TELA Bio Inc Earnings Call Transcript - GuruFocus
TELA Bio revenue up 3% to USD 19.1M in Q1 2026 - Medical Buyer
TELA Bio, Inc. (NASDAQ:TELA) Q1 2026 Earnings Call Transcript - Insider Monkey
TELA Bio, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
TELA Bio Reports First Quarter 2026 Financial Results - The Manila Times
TELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong Eur - GuruFocus
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript Summary - Moomoo
Is TELA Bio (TELA) a Possible Value Trap After Q1 2026? EPS Not - GuruFocus
TELA Bio Backs FY26 Revenue Guidance of at Least 8% Growth Over FY25 >TELA - Moomoo
Earnings call transcript: Tela Bio Q1 2026 earnings miss sparks stock dip By Investing.com - Investing.com South Africa
Tela Bio earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Tela Bio Q1 2026 earnings miss sparks stock dip - Investing.com Australia
TELA Bio Q1 2026 Earnings Call Transcript - Benzinga
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
TELA Bio posts modest Q1 growth, maintains 2026 outlook - TipRanks
TELA Bio (NASDAQ:TELA) Reports Mixed Q1 Results with Revenue Beat but Wider Loss and Cautious Q2 Guidance - ChartMill
TELA Bio Q1 revenue growth beats estimates, loss widens - TradingView
TELA Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TELA Bio, Inc. Provides Revenue Guidance for the Second Quarter 2026 and Reiterates Revenue Guidance for the Full Year 2026 - marketscreener.com
TELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong European Growth and Strategic U.S. ... By GuruFocus - Investing.com Canada
What To Expect From TELA Bio Inc (TELA) Q1 2026 Earnings - GuruFocus
TELA Q1'26 Earnings: EPS estimate is (0.18) USD - TradingView
TELA Bio Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Why TELA Bio (TELA) could be the turning point you've been waiting for (Moonwalks) 2026-05-08Buy Signals - newser.com
TELA Bio (TELA) shares surge 11% after beating Q4 earnings estimates, defying analyst pessimism.Earnings Risk - newser.com
Earnings Preview: TELA Bio to Report Financial Results Post-market on May 12 - Moomoo
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
TELA Bio Plans Board Overhaul, Reports Preliminary Q1 Revenue Beat - MyChesCo
TELA Bio (TELA) posts narrower than expected Q4 2025 loss, sending shares up 4.59 percent in today’s trading.Convertible Notes - newser.com
LIQUIFIX offers new approach to mesh fixation, TELA Bio claims - Traders Union
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and TELA Bio (TELA) - The Globe and Mail
Tela Bio Inc Stock (TELA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):